Substance / Medication

Calciotropic hormone

Overview

Active Ingredient
ergocalciferol
RxNorm CUI
4018

Indications

Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.

Labeler: REMEDYREPACK INC.Updated: 2026-01-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

80 trials linked to this intervention

80
Total Trials
5
Recruiting
22
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Short-term effects of Roux-en-Y gastric bypass or gastric sleeve on bone mineral density and calciotropic hormones: a systematic review and meta-analysis.
de Almeida Paula Caroline, Lima Thiago da Rosa, Avila Eudes Thiago Pereira et al. · Surg Obes Relat Dis · 2024
PMID: 38594090Meta-Analysis
The Relationship Between Calciotropic Hormones, IGF-1, and Bone Mass Across Pubertal Stages.
Matar Maria, Al-Shaar Laila, Maalouf Joyce et al. · J Clin Endocrinol Metab · 2016
PMID: 27676398RCT
Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease.
Oksa Adrián, Spustová Viera, Krivosíková Zora et al. · Kidney Blood Press Res · 2008
PMID: 18802363RCT
Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly.
Romagnoli Elisabetta, Mascia Maria Lucia, Cipriani Cristiana et al. · J Clin Endocrinol Metab · 2008
PMID: 18492750RCT
Interrelationship between bone turnover markers, calciotropic hormones and leptin in obese Saudi children.
Saber L M, Mahran H N F, Baghdadi H H et al. · Eur Rev Med Pharmacol Sci · 2015
PMID: 26636521Observational
Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome.
Mahmoudi Touraj, Gourabi Hamid, Ashrafi Mahnaz et al. · Fertil Steril · 2010
PMID: 19230880Observational
Response of calciotropic hormones and bone turnover to brisk walking according to age and fitness level.
Maïmoun L, Simar D, Caillaud C et al. · J Sci Med Sport · 2009
PMID: 18768364Observational
10-Day-Old Male Infant With Electrolyte Derangement and Abnormal Calciotropic Hormone Profile.
Zent Lauren, Riese Abby, Goodrich Nathaniel et al. · Clin Pediatr (Phila) · 2023
PMID: 36242525Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Vitamin D and/or vitamin D derivative (substance)
SNOMED CT
30178006
UMLS CUI
C0014695
RxNorm CUI
4018
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
80
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.